Resource Summary Report

Generated by NIF on Aug 13, 2026

Phospho-S6 Ribosomal Protein (Ser235/236) Antibody

RRID:AB_331679
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2211, RRID:AB_331679

Antibody Information

URL: http://antibodyregistry.org/AB_331679

Proper Citation: Cell Signaling Technology Cat# 2211, RRID:AB_331679

Target Antigen: Phospho-S6 Ribosomal Protein (Ser235/236)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P, IHC-F, IF-IC, F. Consolidation: AB_331680.

Antibody Name: Phospho-S6 Ribosomal Protein (Ser235/236) Antibody

Description: This polyclonal targets Phospho-S6 Ribosomal Protein (Ser235/236)

Target Organism: monkey, rat, mouse, human

Antibody ID: AB_331679

Vendor: Cell Signaling Technology

Catalog Number: 2211

Alternative Catalog Numbers: 2211S, 2211L

Record Creation Time: 20250819T225710+0000

Record Last Update: 20250820T034907+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-S6 Ribosomal Protein (Ser235/236) Antibody.

No alerts have been found for Phospho-S6 Ribosomal Protein (Ser235/236) Antibody.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 204 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Sechrist ZR, et al. (2026) Ablation of tumor-derived IGFBP-3 attenuates cancer-associated skeletal muscle wasting in murine pancreatic cancer. American journal of physiology. Cell physiology, 330(2), C467.

Koenig J, et al. (2026) Replating Induces mTOR-Dependent Rescue of Protein Synthesis in Charcot-Marie-Tooth Diseased Neurons. eNeuro, 13(3).

Bakhmet EI, et al. (2026) PCBP1 orchestrates amino acid metabolism burst during the naïve-to-primed pluripotency transition. Stem cell reports, 21(7), 102950.

Kishida C, et al. (2026) Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy. Journal of the Endocrine Society, 10(2), bvaf171.

Rosen JC, et al. (2026) Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms. British journal of cancer, 134(1), 165.

Peng H, et al. (2026) Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis. Nature communications, 17(1).

Li E, et al. (2026) Oxytocin signaling in adipocytes is required for normal milk fat production. Cell metabolism, 38(6), 1141.

Xie C, et al. (2026) Lysosome-localized IRTKS condensates promote mTORC1 activity leading to MASLD and HCC. Cell reports, 45(2), 116893.

Kral AJ, et al. (2026) Splice-switching ASOs targeting the AURKA 5' UTR collapse an SRSF1-AURKA-MYC oncogenic circuit in pancreatic cancer. Molecular cell, 86(1), 60.

Sunami T, et al. (2026) IGF2BP3 is essential for the growth heterogeneity of colorectal adenoma cells by regulating MYC. iScience, 29(7), 116535.

Juric D, et al. (2026) PI3K? Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical

Models. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(1), 56.

Kadam R, et al. (2026) Optineurin modulates mTORC2/AKT/STAT3 signaling to control MHC class II expression and adaptive immunity against HSV-1. Cell reports, 45(4), 117263.

Zhang X, et al. (2026) Characterization and application of hyperthermia-evoked seizures in a mouse model of focal cortical dysplasia. Neurobiology of disease, 224, 107405.

Dias D, et al. (2025) MITF, TFEB, and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma. Cell reports, 44(12), 116499.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. Cell reports. Medicine, 6(9), 102317.

Imani Farahani N, et al. (2025) High-throughput bioprinting to produce micropatterned neuroepithelial tissues and model TSC2-deficient brain malformations. Cell reports methods, 101177.

Middleton G, et al. (2025) A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer. NPJ precision oncology, 9(1), 67.

Fedoryshchak RO, et al. (2025) PDZ-directed substrate recruitment is the primary determinant of specific 4E-BP1 dephosphorylation by PP1-Neurabin. eLife, 13.

Hawsawi O, et al. (2025) Mitochondrial uncouplers inhibit oncogenic E2F1 activity and prostate cancer growth. Cell reports. Medicine, 6(1), 101890.